Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$64.62
+0.1%
$42.20
$6.71
$64.70
$4.24B1.141.92 million shs974,362 shs
Aravive, Inc. stock logo
ARAV
Aravive
$0.04
$0.04
$0.04
$2.46
$2.95M2.1N/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$6.13
-0.6%
$6.59
$3.04
$8.69
$78.89M0.7834,285 shs1,986 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$19.58
+0.3%
$18.97
$10.06
$21.72
$368.50M0.8250,089 shs14,002 shs
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$0.83
+5.0%
$0.51
$0.41
$1.27
$84.82M0.82140,486 shs604,872 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
+0.03%+0.17%+71.96%+197.01%+810.72%
Aravive, Inc. stock logo
ARAV
Aravive
0.00%0.00%0.00%-13.39%-97.47%
LifeVantage Co. stock logo
LFVN
LifeVantage
-3.67%-6.52%-1.59%+7.12%+83.23%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
-1.26%+3.77%-3.70%+9.85%+80.74%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
+1.95%+54.02%+74.42%+39.82%-9.61%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
1.4532 of 5 stars
2.13.00.00.02.74.20.0
Aravive, Inc. stock logo
ARAV
Aravive
1.6921 of 5 stars
3.00.00.04.60.61.70.6
LifeVantage Co. stock logo
LFVN
LifeVantage
2.755 of 5 stars
0.05.01.72.72.51.71.3
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
1.481 of 5 stars
2.53.00.00.01.81.71.3
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.6918 of 5 stars
0.04.00.00.02.51.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
2.27
Hold$50.33-22.11% Downside
Aravive, Inc. stock logo
ARAV
Aravive
2.00
Hold$13.5033,565.84% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0022.57% Upside
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A

Current Analyst Ratings

Latest ALPN, TLSA, ARAV, LFVN, and NATR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/12/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$42.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Peer Perform
4/9/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
3/19/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $47.00
3/13/2024
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.50 ➝ $24.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$58.88M71.94N/AN/A$5.64 per share11.46
Aravive, Inc. stock logo
ARAV
Aravive
$9.14M0.32N/AN/A$0.18 per share0.22
LifeVantage Co. stock logo
LFVN
LifeVantage
$213.40M0.37$0.50 per share12.35$2.71 per share2.26
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.83$1.58 per share12.39$8.36 per share2.34
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A$0.19 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)
Aravive, Inc. stock logo
ARAV
Aravive
-$76.32M-$0.96N/AN/A-569.65%N/A-99.65%5/8/2024 (Estimated)
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.54M$0.2326.65N/A1.40%19.96%9.48%5/2/2024 (Confirmed)
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7725.43N/A3.39%12.25%7.75%5/7/2024 (Confirmed)
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$15.40MN/A0.00N/AN/AN/AN/AN/AN/A

Latest ALPN, TLSA, ARAV, LFVN, and NATR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/AN/A  
5/2/2024N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/AN/AN/A  
3/18/2024Q4 2023
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$0.32$0.15+$0.47$0.15$6.90 million$30.85 million
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million
1/30/2024Q2 2024
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A$0.10+$0.10$0.25N/A$51.62 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/AN/AN/AN/AN/A
Aravive, Inc. stock logo
ARAV
Aravive
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.142.28%N/A60.87%1 Years
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A

Latest ALPN, TLSA, ARAV, LFVN, and NATR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/25/2024
LifeVantage Co. stock logo
LFVN
LifeVantage
Quarterly$0.03502.64%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/A
7.86
7.86
Aravive, Inc. stock logo
ARAV
Aravive
N/A
0.98
0.98
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.68
1.03
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
75.17%
Aravive, Inc. stock logo
ARAV
Aravive
35.80%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
79.40%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
14265.55 million37.82 millionOptionable
Aravive, Inc. stock logo
ARAV
Aravive
2373.56 million29.13 millionOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
24812.87 million12.00 millionOptionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.94 millionOptionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
9102.27 millionN/AOptionable

ALPN, TLSA, ARAV, LFVN, and NATR Headlines

SourceHeadline
Tiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patientsTiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patients
proactiveinvestors.com - April 25 at 10:59 AM
Tiziana Life Sciences gets US FDA permission to enroll additional patients in intranasal foralumab multiple sclerosis expanded access programmeTiziana Life Sciences gets US FDA permission to enroll additional patients in intranasal foralumab multiple sclerosis expanded access programme
pharmabiz.com - April 25 at 10:32 AM
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal ForalumabTiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
globenewswire.com - April 25 at 10:00 AM
Tiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access ProgramTiziana Life Sciences wins FDA approval to add patients to Multiple Sclerosis Expanded Access Program
proactiveinvestors.com - April 23 at 8:43 AM
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access ProgramTiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
globenewswire.com - April 23 at 7:00 AM
Tiziana Life Sciences reports additional positive results from Multiple Sclerosis programTiziana Life Sciences reports additional positive results from Multiple Sclerosis program
proactiveinvestors.com - April 22 at 8:49 AM
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access ProgramTiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
globenewswire.com - April 22 at 7:00 AM
Tiziana Life Sciences foralumab study highlighted in Neurology TodayTiziana Life Sciences' foralumab study highlighted in Neurology Today
proactiveinvestors.com - April 19 at 9:09 AM
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
globenewswire.com - April 19 at 7:00 AM
Tiziana Life Sciences says foralumab shows promise in stabilizing certain types of MSTiziana Life Sciences says foralumab shows promise in stabilizing certain types of MS
proactiveinvestors.com - April 18 at 9:30 AM
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of NeurologyTiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
globenewswire.com - April 18 at 7:00 AM
Tiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conferenceTiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conference
proactiveinvestors.com - April 11 at 9:11 AM
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of NeurologyTiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
globenewswire.com - April 11 at 7:00 AM
TLSA Tiziana Life Sciences LtdTLSA Tiziana Life Sciences Ltd
seekingalpha.com - March 20 at 4:45 PM
Tiziana Life Sciences files patent for nasal delivery formulation of anti-CD3 antibodiesTiziana Life Sciences files patent for nasal delivery formulation of anti-CD3 antibodies
pharmaceutical-technology.com - March 12 at 1:28 PM
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s DiseaseTiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
finance.yahoo.com - March 5 at 10:39 AM
Tiziana Life Sciences to present positive data for lead drug candidate in Alzheimers diseaseTiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's disease
proactiveinvestors.com - March 5 at 8:27 AM
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimers DiseaseTiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's Disease
globenewswire.com - March 5 at 7:00 AM
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024
finance.yahoo.com - January 5 at 1:32 PM
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated InflammationTiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation
finance.yahoo.com - January 5 at 8:32 AM
Tiziana Life Sciences starts Phase 2a trial and promises results in 2024Tiziana Life Sciences starts Phase 2a trial and promises results in 2024
proactiveinvestors.com - December 22 at 9:47 AM
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple SclerosisTiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
finance.yahoo.com - December 19 at 9:00 AM
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment WebinarTiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar
finance.yahoo.com - December 4 at 9:52 AM
Tiziana Life Sciences advances multiple sclerosis research...Tiziana Life Sciences advances multiple sclerosis research program...Tiziana Life Sciences advances multiple sclerosis research...Tiziana Life Sciences advances multiple sclerosis research program...
proactiveinvestors.com - November 30 at 8:37 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Alpine Immune Sciences logo

Alpine Immune Sciences

NASDAQ:ALPN
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
Aravive logo

Aravive

NASDAQ:ARAV
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
LifeVantage logo

LifeVantage

NASDAQ:LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.
Tiziana Life Sciences logo

Tiziana Life Sciences

NASDAQ:TLSA
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.